Fact CheckerSign in

NCT07415980Not yet recruitingPhase 1/2

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

A Multicenter, Phase Ib/II Clinical Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide for Untreated Elderly Diffuse Large B-cell Lymphoma Patients With Double Expression of MYC and BCL2

Source: ClinicalTrials.gov · Last updated 17 Feb 2026

Brief summary (registry, in English)

This is a single-arm, prospective, multicenter, open-label phase Ib/II study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab and chidamide in previously untreated elderly patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
68 (estimated)
First submitted
10 Feb 2026
Start date
Apr 2026
Primary completion date
Apr 2028
Lead sponsor
Sun Yat-sen University
NCT number
NCT07415980

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 68
  • From Apr 2026 to the primary completion date, Apr 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Known hypersensitivity to any investigational drug.

Other illness

  • Active infections.
  • History of Human Immunodeficiency Virus (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS).
  • Patients with mental disorders or those unable to provide informed consent
  • Any other condition deemed by the investigator to be unsuitable for study enrollment.

Other

  • Other subtypes of DLBCL.
  • Lymphoma involvement in the central nervous system or meninges.

Who the study is looking for

  • Voluntarily participate in the clinical study; fully understand and be informed about the study and sign the Informed Consent Form (ICF); willing to comply with and capable of completing all trial procedures;
  • Age ≥70 years, or age 60-69 years with frailty determined by comprehensive geriatric assessment (CGA).
  • Pathologically confirmed diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) with MYC/BCL2 double expression, and no double-hit or triple-hit lymphoma.
  • At least one measurable or evaluable lesion according to the Lugano 2014 criteria.
  • No prior systemic therapy for DLBCL.
  • Adequate organ and bone marrow function.

Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.